

## united state partment of commerce

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. Т P19977 09/661,305 09/13/00 SATO **EXAMINER** HM12/0803 007055 GREENBLUM & BERNSTEIN, P.L.C. DAVIS, N ART UNIT 1941 ROLAND CLARKE PLACE PAPER NUMBER RESTON VA 20191 1642 DATE MAILED: 08/03/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

•		T		
Office Action Summary		Application No.	<b>•</b> A	pplicant(s)
		09/661,305	S	ATO ET AL.
		Examiner	A	rt Unit
	The MAIL INC DATE of this communication and	Natalie A. Davis	i i	642
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status				
1)🖂	Responsive to communication(s) filed on 20 J	<u>lune 2001</u> .		
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ Th	is action is non-fina	al.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4) Claim(s) 1-6 is/are pending in the application.				
4a) Of the above claim(s) is/are withdrawn from consideration.				
5) Claim(s) is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.				
8) Claim(s) <u>1-6</u> are subject to restriction and/or election requirement.				
Application Papers				
9) The specification is objected to by the Examiner.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)[	All b) Some * c) None of:	- h h	d	
	1. Certified copies of the priority documents			Al.
2. Certified copies of the priority documents have been received in Application No				
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachment(s)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)				

Application/Control Number: 09/661,305

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-2, drawn to an agent for use in screening of a medicament for treatment, prevention and/or diagnosis of an apoptosis associated disease which comprises an apoptosis related protein, classified in class 435, subclass 7.1.
  - II. Claims 1-2, drawn to an agent for use in screening of a medicament for treatment, prevention and/or diagnosis of an apoptosis associated disease which comprises a DNA encoding an apoptosis related protein, classified in class 436, subclass 94.
  - III. Claims 3-5, drawn to a method for screening a medicament, classified in class 435, subclass 4.
  - IV. Claim 6, drawn to a medicament for treatment, prevention and/or diagnosis of an apoptosis associated disease, classified in class 424, subclass 9.1.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of Groups I, II, and IV may be used for a number of different processes that are very much unrelated. For example, protein agent of Group I may not only be used in the method of Group I, but may also be used for used for affinity purification or antibody purification.
- 3. The products of Groups I, II and IV are drawn to structurally and functionally different molecules with different immunological properties, each invention requires different reagents and steps to make and characterize it.

Application/Control Number: 09/661,305

Art Unit: 1642

- 4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, divergent subject matter, and/or require different search strategies, restriction for examination purposes as indicated is proper.
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Natalie A. Davis whose telephone number is 703-308-6410. The examiner can normally be reached on M-F 8-5:30 (every other Friday off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4315 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Natalie a. Davis, Ph.D. July 30, 2001

